Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: Results of a multicenter, randomized, open-label, crossover study

Journal of Sexual Medicine

Volumn 3, Issue 4, 2006, Pages 650-661

  Dean, John ^a   Hackett, Geoffrey I ^b   Gentile, Vincezo ^c   Pirozzi Farina, Furio ^d   Rosen, Raymond C ^e   Zhao, Yanli ^f   Warner, Margaret R ^f   Beardsworth, Anthony ^f  

^a Prostate Centre London   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

^e RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Design; Erectile dysfunction; Methodology of clinical trials; Oral vasoactive agents; Psychological assessment of sexual dysfunction

Indexed keywords

SILDENAFIL; TADALAFIL;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG CHOICE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG PREFERENCE; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTICENTER STUDY; NOSE CONGESTION; OPEN STUDY; OPTIMAL DRUG DOSE; PENIS ERECTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33745282103     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2006.00261.x     Document Type: Article

References (29)

1. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, Carson CC, Cheitlin M, Debusk R, Fonseca V, Ganz P, Goldstein I, Guay A, Hatzichristou D, Hollander JE, Hutter A, Katz S, Kloner RA, Mittleman M, Montorsi F, Montorsi P, Nehra A, Sadovsky R, Shabsigh R. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96: 313-21.
2. Cialis (tadalafil) label. Available at: http://www.fda.gov/cder/foi/label/2005/021368s006lbl.pdf (electronic citation, accessed December 2005).
3. Levitra (vardenafil HCI) label. Available at: http://www.fda.gov/cder/foi/label/2005/021400s004lbl.pdf (electronic citation, accessed December 2005).
4. Viagra (sildenafil citrate) label. Available at: http://www.fda.gov/cder/foi/label/2002/20895s11s15s18lbl (electronic citation, accessed December 2005).
5. Lewis RL, Sadovsky R, Eardley I, O'Leary M, Seftel A, Wang WC, Shen W, Walker DJ, Wong DG, Ahuja S. The efficacy of tadalafil in clinical populations. J Sex Med 2005; 2: 517-31.
6. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: Analysis of data from tadalafil clinical trials. Diabetologia 2004; 47: 1914-23.
7. Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763-71.
8. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-404.
9. Montorsi F, Padma-Nathan H, McCullough A, Brock GB, Broderick G, Ahuja S, Whitaker S, Hoover A, Novack D, Murphy A, Varanese L. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: A randomized, double-blind, placebo-controlled trial. J Urol 2004; 72: 1036 -41.
10. Del Popolo G, Li Marzi V, Mondaini N, Lombardi G. Time/duration effectiveness of sildenafil versus tadalafil in the treatment of erectile dysfunction in male spinal cord-injured patients. Spinal Cord 2004; 42: 643-8.
11. Carosa E, Martini P, Brandetti F, Di Stasi SM, Lombardo F, Lenzi A, Jannini EA. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol 2004; 61: 382-6.
12. Althof SE. When an erection alone is not enough: Biopsychosocial obstacles to lovemaking. Int J Impot Res 2002; 14(suppl 1): S99-104.
13. Althof SE. Quality of life and erectile dysfunction. Urology 2002; 59: 803-10.
14. Heaton JP, Hackett G, Savage D, Padley RJ. Patient choice is critical in managing erectile dysfunction. Eur Urol 2002; 1(suppl 3): 33-7.
15. Hackett G. What do patients expect from erectile dysfunction therapy? Eur Urol 2002; 1(suppl 8): 4-11.
16. Hackett GI. Patient preferences in treatment of erectile dysfunction: The continuing importance of patient education. Clin Cornerstone 2005; 7: 57-65.
17. Carson C, Giuliano F, Goldstein I, Hatzichristou D, Hellstrom W, Lue T, Montorsi F, Munarriz R, Nehra A, Porst H, Rosen R. The "effectiveness"scale - Therapeutic outcome of pharmacologic therapies for ED: An international consensus panel report. Int J Impot Res 2004; 16: 207-13.
18. Cappelleri JC, Althof SE, Siegel RL, Shpilsky A, Bell SS, Duttagupta S. Development and validation of the Self-Esteem and Relationship (SEAR) questionnaire in erectile dysfunction. Int J Impot Res 2004; 16: 30-8.
19. Althof SE, Corty EW, Levine SB, Levine F, Burnett AL, McVary K, Stecher V, Seftel AD. EDITS: Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999; 53: 793-9.
20. Swindle RW, Cameron AE, Lockhart DC, Rosen RC. The psychological and interpersonal relationship scales: Assessing psychological and relationship outcomes associated with erectile dysfunction and its treatment. Arch Sex Behav 2004; 33: 19-30.
21. Rosen R, Broderick G, Shabsigh R, Swindle R, Lockhart D, Cameron A. Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction. J Sex Med 2005; 2: 461-8.
22. Cameron A, Rosen RC, Swindle R. Sexual relationship characteristics among an internet-based sample of US men with and without erectile dysfunction. J Sex Marital Ther 2005; 31: 229-42.
23. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR, Zhao Y, Beardsworth A. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323-32.
24. Cialis (tadalafil) Summary of Product Characteristics. Available at: http://www.emea.eu.int/humandocs/Humans/EPAR/cialis/cialis.htm (electronic citation, accessed December 2005).
25. Viagra (sildenafil) Summary of Product Characteristics. Available at: http://www.emea.eu.int/humandocs/Humans/EPAR/Viagra/Viagra.htm (electronic citation, accessed December 2005).
26. Mulhall JP. Understanding erectile dysfunction medication preference studies. Curr Opin Urol 2004; 14: 367-73.
27. Young JM, Feldman RA, Auerback SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley CM Jr, Hague JA, Ahuja S. Tadalafil improved erectile function at 24 and 36 hours after dosing: US trial. J Androl 2005; 26: 310-8.
28. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541-7.
29. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346-51.